0001410578-25-001470 Sample Contracts
MUTUAL TERMINATION AND RELEASE AGREEMENTMutual Termination and Release Agreement • July 21st, 2025 • Carisma Therapeutics Inc. • Pharmaceutical preparations • Delaware
THIS MUTUAL TERMINATION AND RELEASE AGREEMENT (the “Agreement”) is made as of December 21, 2018 (the “Effective Date”) by and between Histogenics Corporation, a Delaware corporation (“Histogenics”), and Intrexon Corporation, a Virginia corporation (“Intrexon”). Histogenics and Intrexon are from time to time referred to herein individually as a “Party” and collectively as the “Parties”.
ContractLicense Agreement • July 21st, 2025 • Carisma Therapeutics Inc. • Pharmaceutical preparations • Washington
Certain identified information has been excluded from this exhibit because it is both not material and is the type that the registrant treats as private or confidential. Information that was omitted has been noted in this document with a placeholder identified by the mark “[***]”.
ContractLicense Agreement • July 21st, 2025 • Carisma Therapeutics Inc. • Pharmaceutical preparations
Certain identified information has been excluded from this exhibit because it is both not material and is the type that the registrant treats as private or confidential. Information that was omitted has been noted in this document with a placeholder identified by the mark “[***]”.
ContractLicense Agreement • July 21st, 2025 • Carisma Therapeutics Inc. • Pharmaceutical preparations
Certain identified information has been excluded from this exhibit because it is both not material and is the type that the registrant treats as private or confidential. Information that was omitted has been noted in this document with a placeholder identified by the mark “[***]”.
FIRST AMENDMENT TO AGREEMENTFirst Amendment to Agreement • July 21st, 2025 • Carisma Therapeutics Inc. • Pharmaceutical preparations
This First Amendment to the Agreement (this “First Amendment”) effective as of May 9, 2016 (the “First Amendment Effective Date”) is made by and between Purpose Co., Ltd., f/k/a Takagi Sangyo Co. Ltd., and also f/k/a Takagi Industrial Co., Ltd., a Japanese corporation (“Purpose” or “Takagi”), and Histogenics Corporation, a Delaware corporation (“Histogenics”). All capitalized terms used, but not otherwise defined in this First Amendment, shall have the same meanings ascribed thereto in the Agreement made and entered into by and between Purpose and Histogenics as of June 22, 2012 (the “Agreement”).
ContractAmendment to Subscription and Business Agreement • July 21st, 2025 • Carisma Therapeutics Inc. • Pharmaceutical preparations • Massachusetts
Certain identified information has been excluded from this exhibit because it is both not material and is the type that the registrant treats as private or confidential. Information that was omitted has been noted in this document with a placeholder identified by the mark “[***]”.
ContractLicense Agreement • July 21st, 2025 • Carisma Therapeutics Inc. • Pharmaceutical preparations
Certain identified information has been excluded from this exhibit because it is both not material and is the type that the registrant treats as private or confidential. Information that was omitted has been noted in this document with a placeholder identified by the mark “[***]”.
LICENSE AND COMMERCIALIZATION AGREEMENTLicense and Commercialization Agreement • July 21st, 2025 • Carisma Therapeutics Inc. • Pharmaceutical preparations • New York
THIS LICENSE AND COMMERCIALIZATION AGREEMENT (this “Agreement”) is effective as of 21st December, 2017 (the “Effective Date”) by and between Histogenics Corporation., a corporation organized and existing under the laws of the State of Delaware, with offices at 830 Winter Street, 3rd Floor, Waltham, MA, 02451 (“Histogenics”), and MEDINET Co., Ltd., a corporation organized and existing under the laws of Japan, with offices at 2-3-12 Shinyokohama, Kohoku-ku, Yokohama-shi, Kanagawa-ken, Japan (“MEDINET”) (each, a “Party” and together, the “Parties”).
ASSET CONTRIBUTION AGREEMENTAsset Contribution Agreement • July 21st, 2025 • Carisma Therapeutics Inc. • Pharmaceutical preparations • Delaware
This Asset Contribution Agreement (this “Asset Contribution Agreement”), dated as of June 19, 2025, is by and between Ocugen, Inc., a Delaware corporation (“Ocugen”), and OrthoCellix, Inc., a Delaware corporation (“OrthoCellix”).
ContractLicense Agreement • July 21st, 2025 • Carisma Therapeutics Inc. • Pharmaceutical preparations
Certain identified information has been excluded from this exhibit because it is both not material and is the type that the registrant treats as private or confidential. Information that was omitted has been noted in this document with a placeholder identified by the mark “[***]”.
ContractLicense Agreement • July 21st, 2025 • Carisma Therapeutics Inc. • Pharmaceutical preparations
Certain identified information has been excluded from this exhibit because it is both not material and is the type that the registrant treats as private or confidential. Information that was omitted has been noted in this document with a placeholder identified by the mark “[***]”.
EXCLUSIVE CHANNEL COLLABORATION AGREEMENTExclusive Channel Collaboration Agreement • July 21st, 2025 • Carisma Therapeutics Inc. • Pharmaceutical preparations • New York
THIS EXCLUSIVE CHANNEL COLLABORATION AGREEMENT (the “Agreement”) is made and entered into effective as of September 30, 2014 (the “Effective Date”) by and between INTREXON CORPORATION, a Virginia corporation with offices at 20374 Seneca Meadows Parkway, Germantown, MD 20876 (“Intrexon”), and HISTOGENICS CORPORATION, a Delaware corporation having a place of business at 830 Winter Street, Waltham, MA 02451 (“Histogenics”). Intrexon and Histogenics may be referred to herein individually as a “Party”, and collectively as the “Parties.”
ContractLicense Agreement • July 21st, 2025 • Carisma Therapeutics Inc. • Pharmaceutical preparations • Delaware
Certain identified information has been excluded from this exhibit because it is both not material and is the type that the registrant treats as private or confidential. Information that was omitted has been noted in this document with a placeholder identified by the mark “[***]”.
ContractLicense Agreement • July 21st, 2025 • Carisma Therapeutics Inc. • Pharmaceutical preparations
Certain identified information has been excluded from this exhibit because it is both not material and is the type that the registrant treats as private or confidential. Information that was omitted has been noted in this document with a placeholder identified by the mark “[***]”.
REINSTATEMENT AGREEMENT AND SIXTH AMENDMENT TO LICENSE AGREEMENTReinstatement Agreement and Sixth Amendment to License Agreement • July 21st, 2025 • Carisma Therapeutics Inc. • Pharmaceutical preparations
THIS REINSTATEMENT AGREEMENT AND SIXTH AMENDMENT TO LICENSE AGREEMENT (this “Reinstatement and Sixth Amendment”), effective February 8, 2011, is by and among: